CovidStanfordV1, Main, Exploration, bibRecord, 000038

Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.

Identifieur interne : 000038 ( Main/Exploration ); précédent : 000037; suivant : 000039

Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.

Auteurs : Ivana Jankovic [États-Unis] ; Marina Basina [États-Unis]

Source :

Journal of diabetes science and technology [ 1932-2968 ] ; 2021.

RBID : pubmed:33084380

Descripteurs français

KwdFr :
- Diabète (sang), Glycémie (analyse), Humains (MeSH), Hyperglycémie (sang), Maladie grave (MeSH), Monitorage physiologique (MeSH), Patients hospitalisés (MeSH).
MESH :
- analyse : Glycémie.
- sang : Diabète, Hyperglycémie.
- Humains, Maladie grave, Monitorage physiologique, Patients hospitalisés.

English descriptors

KwdEn :
- Blood Glucose (analysis), COVID-19 (blood), Critical Illness (MeSH), Diabetes Mellitus (blood), Humans (MeSH), Hyperglycemia (blood), Inpatients (MeSH), Monitoring, Physiologic (MeSH).
MESH :
- chemical , analysis : Blood Glucose.
- blood : COVID-19, Diabetes Mellitus, Hyperglycemia.
- Critical Illness, Humans, Inpatients, Monitoring, Physiologic.

Abstract

Coronavirus disease 2019 (COVID-19) has disproportionately affected patients with diabetes. Mounting evidence has shown that adequate inpatient glycemic control may decrease the risk of mortality. In critically ill patients, insulin drips are the most effective means of controlling blood glucose. However, resource limitations such as the availability of protective equipment and nursing time have discouraged the use of insulin drips during COVID-19. In this commentary, we review existing evidence on the importance of glycemic control in COVID-19 patients with diabetes and propose a protocol for utilizing continuous glucose monitors (CGMs) to improve glycemic control by decreasing the need for bedside management in critically ill COVID-19 patients.

DOI: 10.1177/1932296820965203
PubMed: 33084380
PubMed Central: PMC7783006

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000232
to stream Main, to step Curation: 000232

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.</title>
<author><name sortKey="Jankovic, Ivana" sort="Jankovic, Ivana" uniqKey="Jankovic I" first="Ivana" last="Jankovic">Ivana Jankovic</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Basina, Marina" sort="Basina, Marina" uniqKey="Basina M" first="Marina" last="Basina">Marina Basina</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33084380</idno>
<idno type="pmid">33084380</idno>
<idno type="doi">10.1177/1932296820965203</idno>
<idno type="pmc">PMC7783006</idno>
<idno type="wicri:Area/Main/Corpus">000232</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000232</idno>
<idno type="wicri:Area/Main/Curation">000232</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000232</idno>
<idno type="wicri:Area/Main/Exploration">000232</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.</title>
<author><name sortKey="Jankovic, Ivana" sort="Jankovic, Ivana" uniqKey="Jankovic I" first="Ivana" last="Jankovic">Ivana Jankovic</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Basina, Marina" sort="Basina, Marina" uniqKey="Basina M" first="Marina" last="Basina">Marina Basina</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of diabetes science and technology</title>
<idno type="eISSN">1932-2968</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Glucose (analysis)</term>
<term>COVID-19 (blood)</term>
<term>Critical Illness (MeSH)</term>
<term>Diabetes Mellitus (blood)</term>
<term>Humans (MeSH)</term>
<term>Hyperglycemia (blood)</term>
<term>Inpatients (MeSH)</term>
<term>Monitoring, Physiologic (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diabète (sang)</term>
<term>Glycémie (analyse)</term>
<term>Humains (MeSH)</term>
<term>Hyperglycémie (sang)</term>
<term>Maladie grave (MeSH)</term>
<term>Monitorage physiologique (MeSH)</term>
<term>Patients hospitalisés (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Blood Glucose</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Glycémie</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>COVID-19</term>
<term>Diabetes Mellitus</term>
<term>Hyperglycemia</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète</term>
<term>Hyperglycémie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Critical Illness</term>
<term>Humans</term>
<term>Inpatients</term>
<term>Monitoring, Physiologic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Maladie grave</term>
<term>Monitorage physiologique</term>
<term>Patients hospitalisés</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19) has disproportionately affected patients with diabetes. Mounting evidence has shown that adequate inpatient glycemic control may decrease the risk of mortality. In critically ill patients, insulin drips are the most effective means of controlling blood glucose. However, resource limitations such as the availability of protective equipment and nursing time have discouraged the use of insulin drips during COVID-19. In this commentary, we review existing evidence on the importance of glycemic control in COVID-19 patients with diabetes and propose a protocol for utilizing continuous glucose monitors (CGMs) to improve glycemic control by decreasing the need for bedside management in critically ill COVID-19 patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33084380</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-2968</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<Issue>1</Issue>
<PubDate><Year>2021</Year>
<Month>01</Month>
</PubDate>
</JournalIssue>
<Title>Journal of diabetes science and technology</Title>
<ISOAbbreviation>J Diabetes Sci Technol</ISOAbbreviation>
</Journal>
<ArticleTitle>Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.</ArticleTitle>
<Pagination><MedlinePgn>174-176</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1932296820965203</ELocationID>
<Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) has disproportionately affected patients with diabetes. Mounting evidence has shown that adequate inpatient glycemic control may decrease the risk of mortality. In critically ill patients, insulin drips are the most effective means of controlling blood glucose. However, resource limitations such as the availability of protective equipment and nursing time have discouraged the use of insulin drips during COVID-19. In this commentary, we review existing evidence on the importance of glycemic control in COVID-19 patients with diabetes and propose a protocol for utilizing continuous glucose monitors (CGMs) to improve glycemic control by decreasing the need for bedside management in critically ill COVID-19 patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jankovic</LastName>
<ForeName>Ivana</ForeName>
<Initials>I</Initials>
<Identifier Source="ORCID">0000-0001-6818-9303</Identifier>
<AffiliationInfo><Affiliation>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Basina</LastName>
<ForeName>Marina</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>T32 DK007217</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Diabetes Sci Technol</MedlineTA>
<NlmUniqueID>101306166</NlmUniqueID>
<ISSNLinking>1932-2968</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007297" MajorTopicYN="Y">Inpatients</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">critical care</Keyword>
<Keyword MajorTopicYN="Y">diabetes</Keyword>
<Keyword MajorTopicYN="Y">insulin drip</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year>
<Month>10</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>12</Hour>
<Minute>19</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33084380</ArticleId>
<ArticleId IdType="doi">10.1177/1932296820965203</ArticleId>
<ArticleId IdType="pmc">PMC7783006</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Diabetes Sci Technol. 2020 Apr 22;:1932296820920948</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32319318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Jul;43(7):1408-1415</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32430456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Jan;43(Suppl 1):S193-S202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31862758</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetologia. 2020 Aug;63(8):1500-1515</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32472191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Sci Technol. 2016 Aug 22;10(5):1174-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27286715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Nov;43(11):e168-e169</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32393587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Sci Technol. 2020 Jul;14(4):783-790</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31777280</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Aug;43(8):e81-e82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32444458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Metab. 2020 Jun 2;31(6):1068-1077.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32369736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocrinol Metab Clin North Am. 2020 Mar;49(1):79-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31980123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Sci Technol. 2019 Jul;13(4):674-681</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30636449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2017 Jul 31;21(1):197</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28756769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2017 Apr;40(4):509-517</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28325798</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Jul;43(7):e75-e76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Nov;43(11):2736-2743</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32759361</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Sci Technol. 2020 Jul;14(4):822-832</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32536205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Oct;43(10):2339-2344</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32769128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Res Rev. 2020 Aug 27;:e3398</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32852883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Jankovic, Ivana" sort="Jankovic, Ivana" uniqKey="Jankovic I" first="Ivana" last="Jankovic">Ivana Jankovic</name>
</region>
<name sortKey="Basina, Marina" sort="Basina, Marina" uniqKey="Basina M" first="Marina" last="Basina">Marina Basina</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000038 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000038 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33084380
   |texte=   Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33084380" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.

Proposed Use of Continuous Glucose Monitoring for Care of Critically Ill COVID-19 Patients.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki